Development, optimization and evaluation of surfactant-based pulmonary nanolipid carrier system of XXXX for the management of drug resistance lung cancer using Box-Behnken design.

@entity7895 @entity9266 @entity1311 @entity4045
UNASSIGNED: In the present study, nanostructured lipid carriers (NLCs) along with various surfactants loaded with @entity1311 ( @entity4045 ) were prepared by an emulsification technique using a Box-Behnken design. The Box-Behnken design indicated that the most effective factors on the size and PDI were at high surfactant concentration (1.5%), low lipids ratio (6:4) and medium homogenization speed (6000   rpm). Among all the formulations, @entity9266 -loaded NLCs show least particle size compared to @entity9266 and @entity9266 . Entrapment efficiency of @entity9266 , @entity9266 and @entity9266 -loaded formulations were 82.40, 85.60 and 79.78%, respectively. Drug release of @entity9266 , @entity9266 and @entity9266 -loaded NLCs is 64.9, 62.3 and 59.7%, respectively (within 72   h). Maximum cellular uptake was observed with @entity9266 formulation on Caco-2 cell lines. Furthermore, spray drying of resultant NLCs was showed good flow properties and was selected for drug delivery to deeper airways. In-vivo studies demonstrated the better localization of drug within the lungs using different surfactant-based pulmonary delivery systems. From this study, we have concluded that delivering drugs through pulmonary route is advantageous for local action in lungs as maximum amount of drug concentration was observed in lungs. The surfactants could prove to be beneficial in treating drug resistance lung cancer by inhibiting @entity7895 efflux in the form of nano lipidic carriers.
